To evaluate the importance of STK39/PLK1/ERK1/2 axis in the progression of HCC, two STK39 inhibitors (Closantel and Rafoxanide) were selected to treat HCC cells. This evidence concerns the gene STK39 and hepatocellular carcinoma.